CHICAGO – Progression-free survival results for Johnson & Johnson's anti-CD-38 antibody Darzalex (daratumumab) in the CASTOR study are highly competitive with other myeloma drugs and represent a change in the standard of care, the trial's lead investigator said on June 5 at the American Society of Clinical Oncology annual meeting.
One of the major data highlights at the American Society of Clinical Oncology meeting, held June 3-7 in Chicago, is...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)